AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

AVEO Oncology (Nasdaq: AVEO) announced that CEO Michael Bailey will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. A replay of the pre-recorded presentation will be available on the company's website starting March 9, 2021, and will be archived for 30 days. AVEO is focused on oncology, committed to developing medicines for cancer patients, with its lead product tivozanib already approved in the EU for advanced renal cell carcinoma. The company is also advancing other clinical candidates, including ficlatuzumab and AV-380.

AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually on March 9-10, 2021.

A replay of the pre-recorded presentation can be accessed on Tuesday, March 9, 2021 in the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

About AVEO Pharmaceuticals, Inc.

AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO’s strategy is to focus its resources toward development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO’s lead candidate, tivozanib, is approved as FOTIVDA^® in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced renal cell carcinoma. Tivozanib is being studied in the TIVO-3 trial, which is supporting a regulatory submission of tivozanib in the U.S. seeking marketing approval as a treatment for relapsed or refractory renal cell carcinoma. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab for the potential treatment of head and neck cancer. AVEO’s pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO’s earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the section titled “Risk Factors” in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005378/en/

FAQ

When will AVEO present at the H.C. Wainwright Global Life Sciences Conference?

AVEO will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

How can I access the AVEO presentation from the conference?

The AVEO presentation can be accessed on March 9, 2021, on their website in the investors section.

What is tivozanib and its status in AVEO's pipeline?

Tivozanib is AVEO's lead candidate, approved in the EU for advanced renal cell carcinoma, and is under study for U.S. marketing approval.

What other candidates are being developed by AVEO?

AVEO is also developing ficlatuzumab for head and neck cancer and AV-380 for cancer cachexia.

What is the significance of the H.C. Wainwright Global Life Sciences Conference for AVEO?

The conference provides AVEO an opportunity to present key developments in their oncology-focused pipeline.